China SXT Pharmaceuticals
SXTC
5 hedge funds and large institutions have $524K invested in China SXT Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
7% more capital invested
Capital invested by funds: $491K → $524K (+$33.5K)
0.01% more ownership
Funds ownership: 0.27% → 0.28% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
29% less funds holding
Funds holding: 7 → 5 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$156K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$34.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$69.9K |
| 2 |
HF
HRT Financial
New York
|
-$42K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$24.3K |
| 4 |
VF
Virtu Financial
New York
|
-$17.3K |
| 5 |
SOW
State of Wyoming
Cheyenne,
Wyoming
|
-$142 |
SXTC Hedge Fund Activity: Q4 2025 in Review
5 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q4 2025, worth a combined $524K — up 6.8% from $491K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SXTC and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, adding an estimated $156K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $69.9K sold.
- 5 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q4 2025, down from 7 in Q3 2025.
- Funds reported $524K of China SXT Pharmaceuticals stock for Q4 2025, up 6.8% quarter-over-quarter.
- 1 fund opened new China SXT Pharmaceuticals positions in Q4 2025 and 3 closed out, a net change of -2 holders.
- The largest China SXT Pharmaceuticals buyer in Q4 2025 was Citadel Advisors, an estimated $156K added.
- The largest China SXT Pharmaceuticals seller in Q4 2025 was Renaissance Technologies, an estimated $69.9K sold.
Based on aggregated 13F filings for Q4 2025.